DURHAM, N.C. October 28, 2020 – Tergus Pharma and Phenom Pharmaceuticals announced today that they have entered into an agreement for Tergus to develop a unique delivery solution to help prevent infection by the SARS-CoV-2 virus.
Phenom Pharmaceuticals will use a proprietary delivery pathway and unique molecule to prevent viral infection. The SARS-CoV-2 virus causes COVID-19, the source of a current global pandemic that has severely impacted the health of millions of people.
“Tergus is thrilled to work together with Phenom on such an impactful project,” said Dr. Vijendra Nalamothu, Ph.D., Chairman & CEO of Tergus Pharma. “This has the potential to have a huge impact on global health and wellness in the future.”
Dr. Michelle L. Rivera, MD, founder and CEO of Phenom Pharmaceuticals, said, “Tergus’ reputation as a global leader in topical pharmaceutical R&D and manufacturing is a perfect fit for our ground-breaking concept to help prevent the spread of COVID-19.”
Once Tergus has completed the initial phases of formulation development, Phenom will begin securing additional funding for further testing and development.
About Tergus Pharma
Tergus Pharma is an end-to-end service provider for topical pharmaceutical research, drug development, testing, and manufacturing, and has been an industry leader for several years with a state-of-the-art facility in Durham, North Carolina. The company has a long and stellar reputation for delivering quality results to clients, from formulation through clinical supplies manufacturing, earning the company the tagline, “Think Topicals, Think Tergus.” Tergus will be expanding its capabilities for topical pharmaceutical R&D and manufacturing as it moves to a brand-new, 100,000 sq. ft. facility in Q1, 2021. Tergus scientifically helps its clients achieve the right balance between speed and quality. For more information, please visit https://www.terguspharma.com/
About Phenom Pharmaceuticals
Phenom Pharmaceuticals is an innovative, privately held pharmaceutical company focused on delivering scientifically elegant and revolutionary solutions to worldwide health issues. Our focus is creating highly effective, safe, and timely modern drugs that will significantly protect and improve human health. Phenom’s board has over 50 years of combined experience in clinical medicine and research at leading institutions, including Harvard Medical School, Merck, Lever Brothers, Duke University Medical Center, Columbia University, and the University of North Carolina at Chapel Hill.
Media Contacts
For Tergus Pharma: Susan Wingen; [email protected]; tel +1 (919) 549-9702
For Phenom Pharmaceuticals: Frank J. Kosarek, Jr.; [email protected]; tel +1 (980) 275-9770